Jelle Wesseling

List of Publications by Year
in descending order

262 papers	15,095 citations	19636 61 h-index	24232 110 g-index
272 all docs	272 docs citations	272 times ranked	19264 citing authors

#	Article	IF	Citations
1	Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. PLoS Medicine, 2010, 7, e1000279.	3.9	764
2	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122.	13.7	702
3	Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.. Journal of Cell Biology, 1995, 129, 255-265.	2.3	478
4	A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.. Molecular Biology of the Cell, 1996, 7, 565-577.	0.9	367
5	Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients. Annals of Surgery, 2015, 261, 378-382.	2.1	337
6	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
7	Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ â€" The LORD study. European Journal of Cancer, 2015, 51, 1497-1510.	1.3	272
8	Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncology, The, 2007, 8, 1079-1087.	5.1	268
9	Somatic mutations in the chromatin remodeling gene <i>ARID1A</i> occur in several tumor types. Human Mutation, 2012, 33, 100-103.	1.1	263
10	Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype. Journal of Clinical Oncology, 2011, 29, 660-666.	0.8	247
11	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1630-1640.	5.1	237
12	The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2010, 119, 551-558.	1.1	220
13	Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Alimentary Pharmacology and Therapeutics, 2006, 24, 1341-1348.	1.9	216
14	Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. Nature, 2016, 530, 490-494.	13.7	202
15	A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. International Journal of Cancer, 2013, 133, 929-936.	2.3	192
16	Receptor conversion in distant breast cancer metastases. Breast Cancer Research, 2010, 12, R75.	2.2	189
17	Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. British Journal of Cancer, 2013, 108, 2172-2177.	2.9	184
18	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	12.5	178

#	Article	IF	Citations
19	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology, 2015, 26, 1280-1291.	0.6	177
20	Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary. Journal of Clinical Oncology, 2008, 26, 4435-4441.	0.8	176
21	Ductal carcinoma in situ: to treat or not to treat, that is the question. British Journal of Cancer, 2019, 121, 285-292.	2.9	168
22	Tissue Distribution of the Death Ligand TRAIL and Its Receptors. Journal of Histochemistry and Cytochemistry, 2004, 52, 821-831.	1.3	158
23	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw148.	3.0	157
24	The insulin-like growth factor 1 receptor in cancer: Old focus, new future. European Journal of Cancer, 2007, 43, 1895-1904.	1.3	155
25	Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Research and Treatment, 2009, 117, 483-495.	1.1	154
26	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Annals of Oncology, 2011, 22, 1561-1570.	0.6	150
27	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncology, The, 2022, 23, 149-160.	5.1	148
28	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports, 2016, 6, 18517.	1.6	143
29	Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Research and Treatment, 2010, 119, 119-126.	1.1	142
30	Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Research and Treatment, 2015, 150, 547-557.	1.1	141
31	Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). Breast, 2017, 31, 274-283.	0.9	121
32	Diagnosis of breast cancer using diffuse optical spectroscopy from 500 to 1600 nm: comparison of classification methods. Journal of Biomedical Optics, 2011, 16, 087010.	1.4	119
33	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. DMM Disease Models and Mechanisms, 2011, 4, 347-358.	1.2	119
34	The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2010, 17, 2411-2418.	0.7	117
35	Identification of recurrent <i><scp>FGFR3</scp></i> fusion genes in lung cancer through kinome‐centred <scp>RNA</scp> sequencing. Journal of Pathology, 2013, 230, 270-276.	2.1	113
36	CHECK (Cohort Hip and Cohort Knee): similarities and differences with the Osteoarthritis Initiative. Annals of the Rheumatic Diseases, 2009, 68, 1413-1419.	0.5	112

#	Article	IF	Citations
37	MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 1136-1147.	5.1	112
38	The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study. Breast Cancer Research and Treatment, 2009, 116, 161-169.	1.1	110
39	Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. Journal of Nuclear Medicine, 2005, 46, 400-4.	2.8	108
40	The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands. Journal of Hematology and Oncology, 2020, 13, 147.	6.9	107
41	Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. Nature Communications, 2011, 2, 513.	5.8	91
42	The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques. European Journal of Surgical Oncology, 2010, 36, 387-392.	0.5	90
43	MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Molecular Diagnostics, 2014, 16, 190-197.	1.2	90
44	Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Research and Treatment, 2012, 136, 35-43.	1.1	88
45	Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1830-1838.	3.3	88
46	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Research, 2014, 16, R47.	2.2	86
47	Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Research and Treatment, 2013, 140, 63-71.	1.1	85
48	Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer, 2012, 118, 4929-4935.	2.0	81
49	Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers. Annals of Surgery, 2010, 251, 488-492.	2.1	78
50	Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. Annals of Surgical Oncology, 2017, 24, 3534-3540.	0.7	76
51	FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast, 2013, 22, 691-697.	0.9	75
52	Effect of bile absorption coefficients on the estimation of liver tissue optical properties and related implications in discriminating healthy and tumorous samples. Biomedical Optics Express, 2011, 2, 600.	1.5	73
53	Is episialin/MUC1 involved in breast cancer progression?. Cancer Letters, 1995, 90, 27-33.	3.2	72
54	Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Research, 2011, 13, R107.	2.2	72

#	Article	IF	Citations
55	Neoadjuvant chemotherapy in ER+ HER2ˆ' breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Research and Treatment, 2012, 131, 827-836.	1.1	71
56	Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Annals of Oncology, 2011, 22, 870-876.	0.6	70
57	Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature. Annals of Surgical Oncology, 2010, 17, 1406-1413.	0.7	66
58	Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual *ERBB2* Blockade in Patients With *ERBB2*-Positive Breast Cancer. JAMA Oncology, 2021, 7, 978.	3.4	65
59	Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. British Journal of Cancer, 2010, 103, 1788-1793.	2.9	64
60	Guiding Breast-Conserving Surgery in Patients After Neoadjuvant Systemic Therapy for Breast Cancer: A Comparison of Radioactive Seed Localization with the ROLL Technique. Annals of Surgical Oncology, 2013, 20, 2569-2575.	0.7	64
61	Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. Nature Genetics, 2017, 49, 1219-1230.	9.4	64
62	The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction.. Journal of Cell Biology, 1994, 127, 2071-2080.	2.3	63
63	Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. Journal of Clinical Pathology, 2007, 60, 608-614.	1.0	63
64	Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy. Lung Cancer, 2013, 80, 165-171.	0.9	63
65	Fat/water ratios measured with diffuse reflectance spectroscopy to detect breast tumor boundaries. Breast Cancer Research and Treatment, 2015, 152, 509-518.	1.1	61
66	First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. Radiotherapy and Oncology, 2015, 114, 322-327.	0.3	61
67	Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study. Journal of Hematology and Oncology, 2021, 14, 64.	6.9	61
68	The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Research, 2016, 18, 47.	2.2	60
69	Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype. Breast Cancer Research and Treatment, 2014, 148, 541-551.	1.1	59
70	Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Research, 2015, 17, 134.	2.2	58
71	MRI-Model to Guide the Surgical Treatment in Breast Cancer Patients After Neoadjuvant Chemotherapy. Annals of Surgery, 2010, 251, 701-707.	2.1	57
72	The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Annals of Oncology, 2010, 21, 40-47.	0.6	56

#	Article	IF	Citations
73	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Research, 2016, 18, 104.	2.2	56
74	Diffuse reflectance spectroscopy: towards clinical application in breast cancer. Breast Cancer Research and Treatment, 2013, 137, 155-165.	1.1	55
75	Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. Journal of the National Cancer Institute, 2017, 109, .	3.0	55
76	Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer. Journal of Pathology, 2009, 217, 372-379.	2.1	54
77	Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. European Journal of Cancer, 2009, 45, 2284-2292.	1.3	54
78	A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. BMC Genomics, 2013, 14, 232.	1.2	54
79	Optical sensing for tumor detection in the liver. European Journal of Surgical Oncology, 2013, 39, 68-75.	0.5	54
80	PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Research, 2014, 16, R13.	2.2	54
81	Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Research and Treatment, 2016, 156, 517-525.	1.1	54
82	Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Annals of Surgery, 2018, 267, 952-958.	2.1	54
83	Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. Journal of Clinical Epidemiology, 2008, 61, 324-330.	2.4	53
84	Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Research and Treatment, 2011, 129, 725-736.	1.1	53
85	Genomic signature of <i>BRCA1</i> deficiency in sporadic basal–like breast tumors. Genes Chromosomes and Cancer, 2011, 50, 71-81.	1.5	53
86	Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis. Breast Cancer Research and Treatment, 2014, 148, 599-613.	1.1	53
87	Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. Breast, 2014, 23, 259-263.	0.9	53
88	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology, 2012, 60, E115-30.	1.6	52
89	SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment, 2013, 137, 213-223.	1.1	52
90	Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. Journal of Medical Genetics, 2005, 42, e20-e20.	1.5	51

#	Article	IF	Citations
91	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. BMC Medicine, 2015, 13, 156.	2.3	51
92	Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Research and Treatment, 2016, 159, 553-563.	1.1	51
93	Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Research, 2012, 14, R93.	2.2	50
94	Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 32-40.	3.3	50
95	The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology, 2007, 51, 322-335.	1.6	49
96	Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors. Cancer Research, 2012, 72, 2350-2361.	0.4	48
97	Diffuse Reflectance Spectroscopy: A New Guidance Tool for Improvement of Biopsy Procedures in Lung Malignancies. Clinical Lung Cancer, 2012, 13, 424-431.	1.1	48
98	Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic. Preventive Medicine, 2021, 151, 106602.	1.6	48
99	Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Research and Treatment, 2012, 132, 379-389.	1.1	47
100	Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Annals of Oncology, 2013, 24, 3017-3023.	0.6	47
101	Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Research, 2014, 16, R6.	2.2	46
102	High <i>XIST</i> and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a <i>BRCA1</i>-like Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 190-198.	1.9	46
103	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. Journal of Clinical Oncology, 2022, 40, 2361-2374.	0.8	45
104	Pathological and Biological Differences Between Screen-Detected and Interval Ductal Carcinoma in situ of the Breast. Annals of Surgical Oncology, 2007, 14, 2097-2104.	0.7	44
105	The <i>CYP2C19*2</i> genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics, 2011, 12, 1137-1146.	0.6	44
106	A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Annals of Oncology, 2010, 21, 481-487.	0.6	43
107	Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Annals of Surgical Oncology, 2013, 20, 2227-2235.	0.7	43
108	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	2.2	43

#	Article	IF	Citations
109	Combined use of 18F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1515-1524.	3.3	42
110	Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period. Breast Cancer Research and Treatment, 2016, 156, 391-400.	1.1	42
111	Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. International Journal of Cancer, 2003, 106, 611-618.	2.3	41
112	The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. Breast Cancer Research and Treatment, 2017, 166, 435-445.	1.1	41
113	Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 835-845.	1.1	41
114	p53 Overexpression is a Predictor of Local Recurrence After Treatment for Both in situ and Invasive Ductal Carcinoma of the Breast. Journal of Surgical Research, 2007, 140, 109-114.	0.8	40
115	Is DCIS Breast Cancer, and How Do I Treat it?. Current Treatment Options in Oncology, 2013, 14, 75-87.	1.3	40
116	Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. Breast Cancer Research and Treatment, 2011, 129, 229-233.	1.1	39
117	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	1.5	39
118	A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results. Breast Cancer Research and Treatment, 2010, 124, 707-715.	1.1	38
119	Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage Iâ€"III Breast Cancer: Comparison With Standard PET/CT. American Journal of Roentgenology, 2016, 206, 1307-1314.	1.0	38
120	Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression. Radiology, 2020, 296, 277-287.	3.6	37
121	Involvement of the cell surface-bound mucin, episialin/MUCI, in progression of human carcinomas. Biochemical Society Transactions, 1995, 23, 822-826.	1.6	36
122	Neurological outcome in school-age children after in utero exposure to coumarins. Early Human Development, 2001, 63, 83-95.	0.8	35
123	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Research and Treatment, 2014, 148, 511-523.	1.1	34
124	Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. Cancer Letters, 2014, 344, 138-146.	3.2	34
125	MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2017, 164, 99-106.	1.1	34
126	Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 958-967.	0.4	34

#	Article	IF	Citations
127	Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nature Genetics, 2022, 54, 850-860.	9.4	34
128	EZH2 Is Overexpressed in <i>BRCA1</i>-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy. Clinical Cancer Research, 2019, 25, 4351-4362.	3.2	33
129	Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer, 2014, 14, 864.	1.1	32
130	Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology, 2017, 35, 2814-2819.	0.8	31
131	Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. JAMA Oncology, 2020, 6, 1381.	3.4	31
132	Axillary recurrence after sentinel lymph node biopsy. European Journal of Surgical Oncology, 2004, 30, 715-720.	0.5	30
133	High ICAM-1 gene expression in pulmonary fibroblasts of COPD patients: a reflection of an enhanced immunological function. European Respiratory Journal, 2006, 28, 113-122.	3.1	30
134	Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma <i>In Situ</i>–A Nested Case–Control Study. Clinical Cancer Research, 2018, 24, 3593-3601.	3.2	30
135	Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Modern Pathology, 2009, 22, 879-886.	2.9	29
136	Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Annals of Oncology, 2012, 23, 2301-2305.	0.6	29
137	MRI of the breast in patients with DCIS to exclude the presence of invasive disease. European Radiology, 2012, 22, 1504-1511.	2.3	29
138	HER2 gene amplification in patients with breast cancer with equivocal IHC results. Journal of Clinical Pathology, 2011, 64, 1069-1072.	1.0	28
139	TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas. Clinical Cancer Research, 2006, 12, 4350-4356.	3.2	27
140	Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. Breast, 2013, 22, 1155-1160.	0.9	27
141	The Use of Mass Spectrometry Imaging to Predict Treatment Response of Patient-Derived Xenograft Models of Triple-Negative Breast Cancer. Journal of Proteome Research, 2015, 14, 1069-1075.	1.8	27
142	Somatic mutations and copy number variations in breast cancers with heterogeneous <i>HER2</i> amplification. Molecular Oncology, 2020, 14, 671-685.	2.1	27
143	Defining hip pain trajectories in early symptomatic hip osteoarthritis – 5 year results from a nationwide prospective cohort study (CHECK). Osteoarthritis and Cartilage, 2016, 24, 768-775.	0.6	25
144	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2015, 1, 18-32.	1.3	24

#	Article	IF	Citations
145	Sarcoidosis mimicking metastatic disease: a case report and review of the literature. Netherlands Journal of Medicine, 2006, 64, 342-5.	0.6	24
146	Nucleus-associated phosphorylation of Ins(1,4,5)P3 to Ins$P$6 in *Dictyostelium*. Biochemical Journal, 1995, 312, 911-917.	1.7	23
147	The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ?pure? ductal carcinoma in situ of the breast. Histopathology, 2007, 51, 227-238.	1.6	23
148	PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. International Journal of Cancer, 2014, 135, 1257-1263.	2.3	23
149	Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review. Critical Reviews in Oncology/Hematology, 2017, 112, 198-207.	2.0	23
150	Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer. Cancer Research, 2020, 80, 1914-1926.	0.4	23
151	Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 99-109.	1.0	23
152	Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels. Growth Hormone and IGF Research, 2009, 19, 126-135.	0.5	22
153	Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. Breast Cancer Research and Treatment, 2014, 145, 697-705.	1.1	22
154	Prevalence and predictors of health care use in patients with early hip or knee osteoarthritis: two-year follow-up data from the CHECK cohort. Osteoarthritis and Cartilage, 2012, 20, 525-531.	0.6	21
155	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. European Journal of Cancer, 2017, 74, 47-54.	1.3	21
156	Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. Breast Cancer Research and Treatment, 2013, 139, 317-327.	1.1	20
157	Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer. Breast Cancer Research, 2016, 18, 82.	2.2	20
158	Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions. European Journal of Cancer, 2011, 47, 887-894.	1.3	19
159	Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer. British Journal of Cancer, 2013, 109, 2965-2972.	2.9	19
160	*BRCA1*-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency. Clinical Cancer Research, 2017, 23, 1236-1241.	3.2	19
161	FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. Molecular Oncology, 2018, 12, 1884-1894.	2.1	19
162	Treatment of breast cancer cells by IGF1R tyrosine kinase inhibitor combined with conventional systemic drugs. Anticancer Research, 2012, 32, 1309-18.	0.5	19

#	ARTICLE	IF	CITATIONS
163	Microarray methods to identify factors determining breast cancer progression: Potentials, limitations, and challenges. Critical Reviews in Oncology/Hematology, 2009, 70, 1-11.	2.0	18
164	Nodal-Stage Classification in Invasive Lobular Breast Carcinoma: Influence of Different Interpretations of the pTNM Classification. Journal of Clinical Oncology, 2010, 28, 999-1004.	0.8	18
165	Immunohistochemical Detection of the CXCR4 Expression in Tumor Tissue Using the Fluorescent Peptide Antagonist Ac-TZ14011-FITC. Translational Oncology, 2011, 4, 234-IN3.	1.7	18
166	Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. Breast Cancer Research and Treatment, 2015, 152, 247-252.	1.1	18
167	Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2020, 106, 174-181.	0.4	18
168	Cell Discohesion and Multifocality of Carcinoma In situ of the Bladder: New Insight From the Adhesion Molecule Profile (e-Cadherin, Ep-CAM, and MUC1). International Journal of Surgical Pathology, 2009, 17, 99-106.	0.4	17
169	Avoiding preoperative breast MRI when conventional imaging is sufficient to stage patients eligible for breast conserving therapy. European Journal of Radiology, 2014, 83, 273-278.	1.2	17
170	Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. Breast Cancer Research and Treatment, 2015, 154, 81-88.	1.1	17
171	Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore. Clinical Cancer Research, 2019, 25, 4985-4992.	3.2	17
172	Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS. American Journal of Surgical Pathology, 2019, 43, 1574-1582.	2.1	17
173	Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features. Radiology, 2022, 303, 54-62.	3.6	17
174	Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thrombosis and Haemostasis, 2001, 85, 609-13.	1.8	17
175	Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer. Clinical Nuclear Medicine, 2016, 41, e181-e186.	0.7	16
176	Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study. Breast Cancer Research and Treatment, 2019, 178, 409-418.	1.1	16
177	Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Research and Treatment, 2020, 183, 759-770.	1.1	16
178	Variability in grading of ductal carcinoma <i>in situ</i> among an international group of pathologists. Journal of Pathology: Clinical Research, 2021, 7, 233-242.	1.3	16
179	Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. PLoS ONE, 2017, 12, e0176782.	1.1	16
180	Pre-treatment imaging and pathology characteristics of invasive breast cancers of limited extent: Potential relevance for MRI-guided localized therapy. Radiotherapy and Oncology, 2012, 104, 11-18.	0.3	15

#	Article	IF	Citations
181	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
182	Molecular subtyping of breast cancer: ready to use?. Lancet Oncology, The, 2010, 11, 306-307.	5.1	14
183	Breast cancerâ€"related deaths according to grade in ductal carcinoma in situ: A Dutch populationâ€"based study on patients diagnosed between 1999 and 2012. European Journal of Cancer, 2018, 101, 134-142.	1.3	14
184	Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy. American Journal of Surgery, 2009, 198, 46-50.	0.9	13
185	Aggressiveness of â€˜trueâ€™ interval invasive ductal carcinomas of the breast in postmenopausal women. Modern Pathology, 2010, 23, 629-636.	2.9	13
186	Regulation of TRAIL receptor expression by Â-catenin in colorectal tumours. Carcinogenesis, 2014, 35, 1092-1099.	1.3	13
187	Neoadjuvant tamoxifen synchronizes ERÎ± binding and gene expression profiles related to outcome and proliferation. Oncotarget, 2016, 7, 33901-33918.	0.8	13
188	The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study. Breast Cancer Research, 2017, 19, 26.	2.2	12
189	Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03). Radiotherapy and Oncology, 2020, 145, 201-208.	0.3	12
190	Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation. British Journal of Cancer, 1996, 73, 439-446.	2.9	11
191	Increased risk of colorectal neoplasia in asymptomatic liver-transplant recipients. Gut, 2007, 56, 892-893.	6.1	11
192	Measurement of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples. Clinical Biochemistry, 2008, 41, 636-639.	0.8	11
193	Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: Lasting local control and acceptable morbidity. European Journal of Surgical Oncology, 2009, 35, 469-474.	0.5	11
194	Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer. Breast Journal, 2013, 19, 419-426.	0.4	11
195	An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 297-304.	1.4	11
196	Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 473-481.	1.4	11
197	Long-term prognosis of young breast cancer patients (â‰¤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. BMJ Open, 2017, 7, e017842.	0.8	11
198	The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. BMC Cancer, 2018, 18, 224.	1.1	11

#	Article	IF	Citations
199	Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. Npj Breast Cancer, 2021, 7, 31.	2.3	11
200	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. Npj Breast Cancer, 2022, 8, 60.	2.3	11
201	Behavioural outcome of school-age children after prenatal exposure to coumarins. Early Human Development, 2000, 58, 213-224.	0.8	10
202	Prediction Model For Extensive Ductal Carcinoma In Situ Around Early-Stage Invasive Breast Cancer. Investigative Radiology, 2016, 51, 462-468.	3.5	10
203	Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?. Breast Cancer Research and Treatment, 2021, 187, 187-196.	1.1	10
204	Radioguided occult lesion localisation (ROLL) in breast-conserving surgery after neoadjuvant chemotherapy. European Journal of Surgical Oncology, 2012, 38, 1218-1224.	0.5	9
205	Lack of Genomic Heterogeneity at High-Resolution aCGH between Primary Breast Cancers and Their Paired Lymph Node Metastases. PLoS ONE, 2014, 9, e103177.	1.1	9
206	Adjuvant dose-dense doxorubicin-cyclophosphamideÂversus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). European Journal of Cancer, 2018, 102, 40-48.	1.3	9
207	Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?. European Journal of Radiology, 2019, 121, 108705.	1.2	9
208	Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index. European Radiology, 2020, 30, 6740-6748.	2.3	9
209	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. Npj Breast Cancer, 2020, 6, 60.	2.3	9
210	Radio-guided seed localization for breast cancer excision. Nuclear Medicine Communications, 2014, 35, 961-966.	0.5	8
211	Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer. Cancer Imaging, 2017, 17, 15.	1.2	8
212	BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer. Breast Cancer Research, 2020, 22, 79.	2.2	8
213	Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists. Cancers, 2021, 13, 3962.	1.7	8
214	Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients. PLoS ONE, 2017, 12, e0189750.	1.1	8
215	Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. BMC Cancer, 2018, 18, 761.	1.1	7
216	Avoiding Overtreatment of Ductal Carcinoma in situ. Trends in Cancer, 2019, 5, 391-393.	3.8	7

#	Article	IF	Citations
217	The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. Breast, 2020, 50, 95-103.	0.9	7
218	Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer. Breast Cancer Research and Treatment, 2021, 189, 213-224.	1.1	7
219	The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure. Breast Cancer Research and Treatment, 2015, 153, 145-152.	1.1	6
220	Utility of diagnostic breast excision biopsies during two decades of screening mammography. Breast, 2019, 46, 157-162.	0.9	6
221	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. British Journal of Cancer, 2021, 125, 1443-1449.	2.9	6
222	Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization.. , 2009, , .		6
223	Enrichment of high-grade tumors in breast cancer gene expression studies. Breast Cancer Research and Treatment, 2018, 168, 327-335.	1.1	5
224	Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. British Journal of Cancer, 0, , .	2.9	5
225	Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review. Cancers, 2022, 14, 3259.	1.7	5
226	Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival. Breast, 2022, 65, 110-115.	0.9	5
227	Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?. European Journal of Radiology, 2013, 82, 2353-2358.	1.2	4
228	Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. Genes, 2018, 9, 261.	1.0	4
229	Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)â€"PathIES. Breast Cancer Research and Treatment, 2019, 175, 149-163.	1.1	4
230	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. Clinical Cancer Research, 2022, 28, 960-971.	3.2	4
231	OP0031â€¦Comparison between check study (cohort hip& cohort knee) and osteoartritis initiative; development of pain and function in 3 years of follow-up. Annals of the Rheumatic Diseases, 2013, 71, 63.2-63.	0.5	3
232	201P 70-gene signature to select breast cancer patients for neoadjuvant endocrine treatment. Annals of Oncology, 2020, 31, S322-S323.	0.6	3
233	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. JAMA Oncology, 2020, 6, 1117.	3.4	3
234	Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience. Annals of Surgical Oncology, 2021, 28, 7383-7394.	0.7	3

#	Article	IF	Citations
235	Cell surface associated mucins: Structure and effects on cell adhesion. , 1995, , 259-271.		3
236	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. The Clinical Journal of Pathology, 2014, , n/a-n/a.	0.0	2
237	Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology. Journal of Clinical Oncology, 2009, 27, 587-587.	0.8	2
238	Symptomatic carrier of haemophilia B Leyden: a case report. Haemophilia, 2010, 16, 965-966.	1.0	1
239	Reply to â€œAnti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on â€˜Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage IIâ€"III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227â€"35â€™â€. Annals of Surgical Oncology. 2014, 21, 700-700.	0.7	1
240	Defining hip pain trajectories in early symptomatic hip osteoarthritis â€" five year results from a nationwide cohort study (check). Osteoarthritis and Cartilage, 2016, 24, S28.	0.6	1
241	PO-337 Single cell mRNA sequencing reveals the presence of the gene expression signature of all major molecular subtypes in individual breast cancers. ESMO Open, 2018, 3, A360.	2.0	1
242	PO-498 Spliced RNA panels from tumor-educated platelets (TEP) enable detection of early breast cancer. ESMO Open, 2018, 3, A424-A425.	2.0	1
243	Women diagnosed with Ductal Carcinoma In Situ (DCIS) and healthcare providersâ€™ views on active surveillance for DCIS. Results from focus groups and in-depth interviews. European Journal of Cancer, 2020, 138, S36.	1.3	1
244	Genomic patterns resembling BRCA-mutated breast cancers and benefit of intensified carboplatin-based chemotherapy in HER2-negative breast cancer.. Journal of Clinical Oncology, 2011, 29, 10505-10505.	0.8	1
245	IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women. Npj Breast Cancer, 2021, 7, 138.	2.3	1
246	Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology. Journal of Pathology, 2022, , .	2.1	1
247	Membrane-associated mucins. Biomembranes: A Multi-Volume Treatise, 1996, , 219-230.	0.1	0
248	Molecular tests for breast-cancer diagnosis?. Lancet Oncology, The, 2009, 10, 314-315.	5.1	0
249	Development of pain and function in 3 years of follow-up; comparison between check study (cohort) Tj ETQq1 1 0.784314 rgBT /Over	0.6	0
250	OP0292â€¦Different Pain Trajectories in Early Symptomatic Knee OA; 5 Year Follow-Up of Check (Cohort) Tj ETQq0 0 0 rgBT /Overlock	0.5	0
251	AB0779â€¦7 Years of Follow-Up of Early Symptomatic Oa: Characteristics of CHECK (Cohort HIP &) Tj ETQq1 1 0.784314 rgBT /	0.5	0
252	PO-070 Identification of risk factors for subsequent invasive breast cancer after primary DCIS by transcriptomic profiling. ESMO Open, 2018, 3, A254.	2.0	0

#	Article	IF	Citations
253	Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer. British Journal of Radiology, 2021, 94, 20201125.	1.0	0
254	OC-0067 De-escalation of radiation therapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM). Radiotherapy and Oncology, 2021, 161, S41-S42.	0.3	0
255	Neurological Outcome in School-Age Children After In Utero Exposure to Coumarins. Obstetrical and Gynecological Survey, 2002, 57, 16-17.	0.2	0
256	Intraductal Papillary Carcinoma. Encyclopedia of Pathology, 2019, , 1-7.	0.0	0
257	Intraductal Papillary Carcinoma. Encyclopedia of Pathology, 2020, , 175-180.	0.0	0
258	Famrisc, a RCT comparing mammography with MRI in screening for familial risk. European Journal of Surgical Oncology, 2020, 46, e19.	0.5	0
259	Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients. Breast, 2021, 60, 230-237.	0.9	0
260	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). Cancer Research, 2022, 82, P1-02-09-P1-02-09.	0.4	0
261	Abstract P1-22-05: Identifying predictors of invasive recurrence based on molecular profiles of DCIS lesions. Cancer Research, 2022, 82, P1-22-05-P1-22-05.	0.4	0
262	Mammary duct detection using self-supervised encoders. , 2022, , .		0